News | May 11, 2024
Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
The company is committed to address this observation comprehensively within stipulated time
CHL is strengthening its play in the fast-growing beauty and personal care sector
_256_384.jpg)
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Mungara has over 25+ years of experience in the supply chain domain
Cipla completes transfer of Generics Business Undertaking
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Subscribe To Our Newsletter & Stay Updated
